S. Korea's English proficiency slips 13 notches to 49th
N. Korea reinstates DMZ guard posts
N. Korea says spy satellite took photos of White House, Pentagon, key US naval base
BOK likely to keep policy rate unchanged on slowdown, hope for Fed's rate freeze, easing inflation
15-year-old girl saves 5 lives with organ donations after death
Samsung sets up control tower for new growth drivers
12 foreigners nabbed on suspicion of drug use
Korea to start hiring E-9 visa foreign workers in restaurants
S. Korea's Busan making last-ditch efforts to bring World Expo on voting day
[KH explains] Hyundai to sell vehicles on Amazon in US sales push
Celltrion’s anticancer biosimilar Vegzelma gets sales approval in UKBy Kan Hyeong-woo
Published : Sept. 19, 2022 - 14:47
The Medicines and Healthcare products Regulatory Agency -- the UK’s drug authorization body -- has granted Celltrion sales approval for oncology biosimilar Vegzelma in the country, the South Korean company announced Monday.
According to Celltrion, Vegzelma was authorized for the treatment of multiple types of cancer including metastatic breast cancer, non-small cell lung cancer, ovarian cancer and cervical cancer.
The UK approval came a month after Vegzelma received a green light from the European Commission in August, allowing the anticancer biosimilar product’s market entrance in the region. Vegzelma is Celltion’s third oncology biosimilar product to be approved in Europe.
Celltrion Healthcare, which is in charge of marketing and sales of Celltrion products, plans to release Vegzelma in major European countries in the second half of this year, according to the company.
“Following Truxima and Herzuma, we will do our best to show Vegzelma -- our third anticancer biosimilar -- to the market promptly and obtain approvals from countries in major global regions smoothly,” said a Celltrion official.
Celltrion requested product sales approval of Vegzelma from the South Korean Ministry of Food and Drug Safety as well as the US Food and Drug Administration last year. The company said it is expecting authorization before the end of this year.
As a bevacizumab biosimilar referencing Avastin, an anticancer drug developed by multinational pharmaceutical company Roche, Vegzelma showed similar safety, efficacy and pharmacokinetics in the clinical trial results, according to Celltrion.
Articles by Kan Hyeong-woo
South Korea warns tit-for-tat action over North Korea’s border buildup
Korea, Japan, China summit likely in early 2024
Yoon orders increased defense of public digital infrastructure